Hepatitis C is a poor prognostic indicator in black kidney transplant recipients.
BACKGROUND
The significance of hepatitis C in kidney transplant recipients is unclear. The prevalence of antibodies to hepatitis C among candidates for transplantation is up to 50% in some centers.


METHODS
We screened 640 frozen serum samples obtained pretransplantation from all kidney recipients at the Medical College of Wisconsin between January 1979 and March 1990 for antibody to hepatitis C using the second generation immunoassay. Charts were reviewed from all hepatitis C antibody-positive (anti-HCV+) patients and 256 randomly chosen hepatitis C antibody negative (anti-HCV-) controls. Actuarial patient and graft survival in these two groups were determined.


RESULTS
The prevalence of anti-HCV was 8.3%. Blacks and i.v. drug users were disproportionately represented in the anti-HCV+ group. Of the anti-HCV+ patients, 18.9% developed chronic hepatitis independent of race. Black anti-HCV+ patients had a 5-year graft survival of 28 +/- 11% compared to 67 +/- 7% in black anti-HCV- patients (P = 0.003). Black anti-HCV-, white anti-HCV-, and white anti-HCV+ patients all had similar graft survival. Anti-HCV was not a poor prognostic indicator for overall patient survival or the development of aplastic anemia and malignancies including hepatocellular carcinoma.


CONCLUSIONS
Anti-HCV is a significant risk factor for reduced kidney graft survival in blacks apart from i.v. drug abuse. Black anti-HCV- patients had graft survival similar to white transplant recipients, indicating that anti-HCV may be one marker for the poorer graft survival in blacks that has been observed in most transplant programs. Anti-HCV in kidney transplant recipients increases the risk for the development of chronic hepatitis post-transplant.
Fritsche
C
C
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
Brandes
J C
JC
Delaney
S R
SR
Gallagher-Lepak
S
S
Menitove
J E
JE
Rich
L
L
Scannell
C
C
Swanson
P
P
Lee
H H
HH
D000328:Adult; D001741:Black or African American; D005260:Female; D006085:Graft Survival; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D009369:Neoplasms / Q000150:complications; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
D006508:Hepatitis Antibodies